Advertisement
Screener

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Capital Expenditures

2.8 / 5 stars · 68/120 Roast Me

MOONLAKE IMMUNOTHERAPEUTICS Capital Expenditures

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Capital Expenditures of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-10

  • MOONLAKE IMMUNOTHERAPEUTICS payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $0.00.
  • MOONLAKE IMMUNOTHERAPEUTICS payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
  • MOONLAKE IMMUNOTHERAPEUTICS payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
  • MOONLAKE IMMUNOTHERAPEUTICS payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
  • MOONLAKE IMMUNOTHERAPEUTICS payments to acquire property, plant, and equipment for fiscal 2025 was $35.00K, a 93.27% decline from fiscal 2024.
  • MOONLAKE IMMUNOTHERAPEUTICS payments to acquire property, plant, and equipment for fiscal 2024 was $520.00K, a 83.10% increase from fiscal 2023.
  • MOONLAKE IMMUNOTHERAPEUTICS payments to acquire property, plant, and equipment for fiscal 2023 was $284.00K, a 1674.00% increase from fiscal 2022.
  • MOONLAKE IMMUNOTHERAPEUTICS payments to acquire property, plant, and equipment for fiscal 2022 was $16.01K.
Period endPayments to Acquire Property, Plant, and Equipment 3 monthPayments to Acquire Property, Plant, and Equipment 3 month as first filedPayments to Acquire Property, Plant, and Equipment 6 monthPayments to Acquire Property, Plant, and Equipment 6 month as first filedPayments to Acquire Property, Plant, and Equipment 9 monthPayments to Acquire Property, Plant, and Equipment 9 month as first filedPayments to Acquire Property, Plant, and Equipment 10 monthPayments to Acquire Property, Plant, and Equipment 12 monthPayments to Acquire Property, Plant, and Equipment 12 month as first filed
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$0.00
10-Q · filed 2026-08-10
$0.00
derived: sum of 3 quarters · filed 2026-08-10
$0.00
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$0.00
10-Q · filed 2026-05-11
$0.00
derived: sum of 2 quarters · filed 2026-05-11
$0.00
derived: sum of 3 quarters · filed 2026-05-11
$0.00
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$0.00
derived: sum of 2 quarters · filed 2026-02-25
$0.00
derived: sum of 3 quarters · filed 2026-08-10
$35.00K
10-K · filed 2026-02-25
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$0.00
derived: sum of 2 quarters · filed 2026-08-10
$35.00K
10-Q · filed 2025-11-05
$211.00K
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$35.00K
10-Q · filed 2026-08-10
$211.00K
derived: sum of 3 quarters · filed 2026-08-10
$343.00K
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31$35.00K
10-Q · filed 2026-05-11
$211.00K
derived: sum of 2 quarters · filed 2026-05-11
$343.00K
derived: sum of 3 quarters · filed 2026-05-11
$343.00K
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31$176.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$308.00K
derived: sum of 2 quarters · filed 2026-02-25
$308.00K
derived: sum of 3 quarters · filed 2026-02-25
$520.00K
10-K · filed 2026-02-25
$519.52K
10-K · filed 2025-02-26
2024-09-30$132.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$132.00K
derived: sum of 2 quarters · filed 2025-11-05
$344.00K
10-Q · filed 2025-11-05
$343.95K
10-Q · filed 2024-11-07
$628.00K
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
$212.00K
10-Q · filed 2025-08-05
$211.76K
10-Q · filed 2024-08-07
$496.00K
derived: sum of 3 quarters · filed 2026-02-25
$496.00K
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$212.00K
10-Q · filed 2025-05-12
$211.76K
10-Q · filed 2024-05-07
$496.00K
derived: sum of 2 quarters · filed 2026-02-25
$496.00K
derived: sum of 3 quarters · filed 2026-02-25
$496.00K
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$284.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$284.00K
derived: sum of 2 quarters · filed 2026-02-25
$284.00K
derived: sum of 3 quarters · filed 2026-02-25
$284.00K
10-K · filed 2026-02-25
$284.63K
10-K · filed 2024-02-29
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$0.00
derived: sum of 2 quarters · filed 2024-11-07
$0.00
10-Q · filed 2024-11-07
$1.00
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
$0.00
10-Q · filed 2024-08-07
$1.00
derived: sum of 3 quarters · filed 2025-02-26
$1.00
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$0.00
10-Q · filed 2024-05-07
$1.00
derived: sum of 2 quarters · filed 2025-02-26
$1.00
derived: sum of 3 quarters · filed 2025-02-26
-$1.00
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$1.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$1.00
derived: sum of 2 quarters · filed 2025-02-26
-$1.00
derived: sum of 3 quarters · filed 2025-02-26
$16.01K
10-K · filed 2025-02-26
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$2.00
derived: sum of 2 quarters · filed 2023-11-14
$16.01K
10-Q · filed 2023-11-14
2022-06-30-$2.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$16.01K
10-Q · filed 2023-08-10
2022-03-31$16.01K
10-Q · filed 2023-05-11
2021-12-31$50.71K
10-K · filed 2023-03-20
2021-09-30$11.65K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$32.33K
10-Q · filed 2022-11-14
2021-06-30$20.68K
10-Q · filed 2022-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Savara Inc (SVRA)United States$1.044B-9.10
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21